Akums Drugs and Pharma L

NSE: AKUMS · Pharmaceuticals · sector

₹686.60NSE close 2026-10-26

Key numbers

Market cap₹10,512 cr

Price₹686.60

52w high / low₹839 / ₹409

P/E36.0xSector median 27.9x

P/B3.2xSector median 2.9x

Book value₹216.4

Dividend yield–Sector median 0.48%

ROE9.2%Sector median 11.7%

ROCE15.4%Sector median 12.3%

OPM12.2%Sector median 14.0%

Debt / equity0.02xSector median 0.16x

EV/EBITDA16.3xSector median 18.6x

Interest cover5.5x

Current ratio3.25x

Sales growth 3y–Sector median +9.6%

Profit growth 3y–Sector median +13.3%

PEG–

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹1,681 cr vs borrowings ₹73 cr (FY26): cash is higher (net cash).
Operating profit covered interest 5.5x in the last 12 months.
Revenue was higher than a year earlier in 3 of the last 4 quarters.
Other income was 45% of net profit in the last 12 months.
No dividend in the last 2 financial years.
Price ₹686.60 on 2026-10-26: -18.1% from the 52-week high, +67.7% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹903.95 · low ₹420.50

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	1,033	1,010	1,056	1,024	1,018	1,160	1,158	1,167
EBITDA	125	126	102	129	94	129	150	175
OPM %	12.1%	12.5%	9.7%	12.6%	9.3%	11.1%	12.9%	15.0%
Other income	13	15	18	27	32	34	35	30
Net profit	65	65	148	63	41	66	85	100
EPS (₹)	4.37	4.26	9.64	4.15	2.66	4.33	5.53	6.53
Revenue YoY					-1.5%	+14.8%	+9.7%	+13.9%
Profit YoY					-37.5%	+1.7%	-42.7%	+57.5%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY25	FY26	TTM
Revenue	4,118	4,359	4,502
EBITDA	481	502	548
Net profit	338	255	292
EPS (₹)	22.60	16.67	19.05
Revenue growth		+5.8%	+9.2%
Profit growth		-24.5%	-14.6%
Dividend / share (₹)	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	–	–	+9.2%
Net profit	–	–	-14.6%
EPS	–	–	–
Share price	–	-12.9% (2y)	+47.6%

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	3,047	3,313
Borrowings	14	73
Cash & equivalents	576	1,681
Total assets	4,113	5,447
Fixed assets	1,390	1,448
Capital work in progress	160	177
Investments	0	0
Receivables	770	797
Inventory	681	756
Payables	643	602

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	465	1,181
Cash from investing	-548	-930
Cash from financing	73	34
Capex	272	231
Free cash flow	193	951

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	11.1%	7.7%
ROCE %	12.4%	14.1%
Debtor days	68	67
Inventory days	102	110
Payable days	96	87
Cash conversion cycle (days)	74	90
Working capital days	122	206

Shareholding

Holder	% (2026-09-30)
Promoters	75.26%
FIIs	4.50%
DIIs	11.08%
of which Mutual funds	7.58%
of which Insurance	0.12%
Public (non-institutions)	6.43%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	75.26%	75.26%	75.26%	75.26%	75.26%	75.26%	75.26%	75.26%

Promoter group	%
AKUMS MASTER TRUST (Sanjeev Jain and Sandeep Jain)	40.79%
Sandeep Jain	17.24%
Sanjeev Jain	17.23%
Lata Jain	0.01%
Anita Jain	0.00%
Anuradha Pal	0.00%
Archana Jain	0.00%
Kiran Jain	0.00%
Kusum Jain	0.00%
Rajesh Sharma	0.00%
Rajiv Mittal	0.00%
Shivangi Jain	0.00%
Arushi Jain	0.00%
Umang Jain	0.00%
Kanishk Jain	0.00%

Public holders above 1%	%
Franklin India Opportunites Fund	3.90%
Akums Employee Benefits Trust	2.73%
Clarus Capital I	2.23%
Bandhan Small Cap Fund	1.13%
ICICI Prudential Healthcare Fund	1.02%

67,618 shareholders. Pledged: – of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
AKUMS	₹10,512 cr	36.0x	3.2x	9.2%	15.4%	12.2%	–	–

All 185 companies in Pharmaceuticals →

Business segments (FY26)

Segment	Revenue	Share	EBIT	Margin
CDMO	₹3,485 cr	80.0%	₹329 cr	9.4%
Domestic Branded Formulations	₹446 cr	10.2%	₹87 cr	19.5%
API	₹184 cr	4.2%	₹-58 cr	-31.3%
International Branded Formulations	₹144 cr	3.3%	₹34 cr	23.9%
Trade Generics	₹100 cr	2.3%	₹-11 cr	-11.4%
Inter-segment eliminations	₹0 cr	–	₹0 cr	–

Dividends & corporate actions

Ex-date	Action	Detail
2026-07-03	Dividend	Dividend - Re 1 Per Share/Special Dividend - Rs 2 Per Share

Documents

Links go to the original files on the exchange website.

About the company

Manufacturing of pharma products and rendering of allied services: CDMO
Manufacturing of pharma products and rendering of allied services: API
Manufacturing of pharma products and rendering of allied services: Domestic Branded Formulations
Manufacturing of pharma products and rendering of allied services: International Branded Formulations
Manufacturing of pharma products and rendering of allied services: Trade Generics


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	AKUMS
BSE code	544222
ISIN	INE09XN01023
Face value	₹2.0
Incorporated	2004-04-19
Website	www.akums.in
Plants (India / abroad)	14 / 0

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.